CTD Subgroup

GRIPHON—The Largest PAH-CTD Subpopulation in a Randomized Controlled PAH Trial (n=334)1-3

The information below is from a post hoc subgroup analysis of the GRIPHON trial.
View the GRIPHON pivotal data for context of the overall population.

PAH-CTD baseline patient characteristics*

PAH-CTD was a prespecified subgroup of the GRIPHON phase 3 trial (UPTRAVI: n=167, placebo: n=167)

This analysis characterized the PAH-CTD subgroup and its response to treatment with UPTRAVI compared with the overall population.

POST HOC ANALYSIS: 41% RISK REDUCTION OF DISEASE PROGRESSION IN PAH-CTD PATIENTS TREATED WITH UPTRAVI

Time to first disease progression event in patients with PAH-CTD

Events in patients with PAH-CTD

Adverse reactions in the PAH-CTD subgroup notably different from the overall population

  • Adverse reactions in the PAH-CTD subgroup were generally consistent with the overall population. See the Important Safety Information below for the most frequent adverse reactions in the overall population

GRIPHON—The Largest PAH-SSc Subpopulation in a Randomized Controlled PAH Trial (n=170)1-3

PAH-SSc baseline patient characteristics

Of the 334 patients with PAH-CTD in GRIPHON, 51% (n=170) had PAH-SSc.

POST HOC ANALYSIS: 44% RISK REDUCTION OF DISEASE PROGRESSION IN PAH-SSc PATIENTS TREATED WITH UPTRAVI

Time to first disease progression event in patients with PAH-SSc

Events in patients with PAH-SSc

Adverse reactions in the PAH-SSc subtype notably different from the overall population

  • Adverse reactions in the PAH-SSc subgroup were generally consistent with the overall population. See the Important Safety Information below for the most frequent adverse reactions in the overall population